Novartis | NVS - Заемный капитал





Заемный капитал Изменить Дата
AbbVie USD 64.53B 5.59B 2026-03
Amgen USD 51.86B 27M 2026-06
AstraZeneca USD 26.01B 46M 2026-06
Bausch Health Companies USD 19.88B 20M 2026-06
Biogen USD 7.29B 1B 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Canopy Growth CAD 217.12M 7.87M 2026-03
Drreddys Laboratories INR 12.2B 12.07B 2026-03
Eli Lilly USD 47.86B 8.49B 2026-06
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 13.95B 65M 2026-06
Glaxosmithkline GBP 18.53B 1.29B 2026-03
J&J USD 37.34B 183M 2026-06
Merck USD 51.08B 4.41B 2026-06
Novartis USD 37.49B 42M 2026-06
Novartis USD 37.45B 7.86B 2026-03
Pacira USD 363.12M 4.53M 2026-06
Perrigo USD 3.28B 337.7M 2026-06
Pfizer USD 60.5B 70M 2026-06
Phibro Animal Health USD 597.68M 5.92M 2026-03
Prestige Brands USD 2.02B 1.01B 2026-06
Roche Holding CHF 25.22B 2.21B 2026-06
Sanofi EUR 14.65B 806M 2026-06
Sanofi EUR 12.3B 3.42B 2026-03
Supernus Pharmaceuticals USD 400.38M 21.13M 2022-03
Zoetis USD 9.05B 3M 2026-06